Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Income Before Tax

Profit after all operating and non-operating items but before income tax.

Valneva SENASDAQ: VALN

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -€31.25M, compared with -€7.76M a year earlier. Trailing-twelve-month income before tax was -€137.61M.

Context

  • Income before tax amounted to 65.3% of revenue in FY2025, up 58.6 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -€31.25M or moves back toward the trailing-twelve-month quarterly average of -€34.4M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€31.25M+38.8% QoQ
Last fiscal yearDec 2025
-€114.12M-893.5% YoY
LTMMar 2026
-€137.61M-76.1% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-302.8%——
1 year-893.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

EUR · from the income statement

Latest · FY2025
(114.12M) EUR
Year-over-year change
-893.5%

Income Before Tax vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -76.1% is the 5th highest of 8, against a peer median of -14.7%.
  • Income before tax amounts to 88.0% of revenue for VALN, versus a peer median of 173.5%.
VALN Competitors
Income Before Tax for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$78.67M USD-14.7%—173.5%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$84.93M USD+12.0%——
NVAXNovavax, Inc.LTM Mar 2026-$86.19M USD-117.6%—14.5%
VALNValneva SELTM Mar 2026-€137.61M EUR-76.1%—88.0%
VIRVir Biotechnology, Inc.LTM Mar 2026-$442.35M USD+23.6%—675.4%
PCVXVaxcyte, Inc.LTM Jun 2026-$1.06B USD-94.4%——
IBRXImmunityBio, Inc.LTM Sep 2026-$1.11B USD-218.3%—607.9%
MRNAModerna, Inc.LTM Sep 2026-$2.73B USD+13.4%—108.1%
Peer median (excluding VALN) —-14.7%—173.5%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.